Skip to content
StackItSmart
DPreclinical / mechanistic only
No human data

MOTS-c

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. It is produced naturally in the body, circulates in plasma, and declines with age. In cell and rodent studies it activates AMPK, improves insulin sensitivity, and enhances exercise capacity, which is why it is marketed and used in the fitness/anti-aging "peptide" community as an injectable performance and metabolic agent. Essentially all efficacy evidence comes from mice, rats, and cell culture: there are no published human trials of administered (exogenous) MOTS-c, no human safety or toxicology data, no established human dose, and no characterized human pharmacokinetics. Human data is limited to observational measurement of the body's own endogenous MOTS-c levels. Material sold for injection is unapproved, unregulated, and of unverified identity/purity/sterility. Because there is no human safety dataset, unknown risks cannot be excluded, and injectable non-pharmaceutical peptides additionally carry infection, contamination, and immune-reaction hazards. This compound should be regarded as experimental with an unquantified risk profile; anyone considering or using it should do so only under medical supervision with bloodwork.

Clinical readoutPeptide · mitochondrial-peptide
Hepatic strainNone
CardiovascularNone
HPTA suppressionNone
Half-life
Not characterized…
Route
In animal research the…
Evidence
D
Active
Unknown in humans
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Not characterized in humans. No human pharmacokinetic study of administered MOTS-c exists. As a small 16-amino-acid peptide it is expected to be rapidly degraded and cleared; endogenous plasma concentrations are measurable but a formal administered half-life has not been established.
Pharmacology

Mechanism of action

MOTS-c is a short peptide translated from a small open reading frame in the mitochondrial 12S rRNA region. Under metabolic stress (e.g., glucose restriction, exercise) it is released from mitochondria and can translocate to the nucleus, where it interacts with stress-responsive transcription factors including NRF2/NFE2L2 and antioxidant response element (ARE)-regulated genes to reprogram nuclear gene expression. Its principal downstream effector is AMP-activated protein kinase (AMPK); it also inhibits the folate cycle and de novo purine biosynthesis, which contributes to AMPK activation. Through AMPK it is reported to increase skeletal-muscle glucose uptake and insulin sensitivity and to promote metabolic adaptation. These mechanisms are established in cell and rodent systems; the same signaling has not been characterized after exogenous administration in humans.
Kinetics

Pharmacokinetics

Half-life

Not characterized in humans. No human pharmacokinetic study of administered MOTS-c exists. As a small 16-amino-acid peptide it is expected to be rapidly degraded and cleared; endogenous plasma concentrations are measurable but a formal administered half-life has not been established.

Active duration

Unknown in humans. Rodent efficacy studies used repeated/daily or intermittent (e.g., several-times-weekly) injection, implying a short circulating duration requiring frequent dosing, but no human data define duration of action.

Route

In animal research the synthetic peptide is given by injection (intraperitoneal or subcutaneous); non-clinical human use is by subcutaneous injection. Oral bioavailability is not established and peptide would be expected to be degraded in the gut. No approved human route exists.

Metabolism & clearance

Not formally studied in humans. Expected proteolytic (peptidase) degradation with renal handling typical of small peptides. No verified human clearance data. PK information here is for monitoring/washout reasoning only, not drug-test evasion.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Activates AMPK signaling and increases skeletal-muscle glucose uptake / insulin sensitivity in cell and rodent models
  • Improved glucose tolerance and reduced insulin resistance in mouse models of diet-induced, age-related, ovariectomy-related, and gestational diabetes (preclinical only)
  • Enhanced physical/exercise performance and healthspan markers in young, middle-aged, and old mice (preclinical only)
  • Promotes brown/white adipose thermogenesis and reduced fat accumulation in rodent models (preclinical only)
  • Anti-inflammatory / antioxidant (NRF2-linked) and anti-ferroptosis effects in cell and animal models (preclinical only)
  • In humans, endogenous (naturally produced) MOTS-c rises acutely in muscle and blood with exercise — an observation about the body's own peptide, not an effect of an injected product
  • No efficacy effect of administered MOTS-c has been demonstrated in any human trial
Safety

Adverse effects by system

Cardiovascular

No human safety data. No cardiovascular adverse effects have been characterized in humans for administered MOTS-c because no human administration studies exist. Preclinical work explores potential cardioprotective/anti-inflammatory signaling but does not establish human safety; cardiovascular risk after exogenous use is unquantified.

Hepatic

No human data. Hepatotoxicity has not been assessed in humans. No human liver-injury signal is reported, but absence of data is not evidence of safety.

Endocrine / HPTA

No human data. MOTS-c is a metabolic/AMPK-linked peptide with no established effect on the hypothalamic-pituitary-gonadal (testosterone) axis; it is not an androgen, SARM, or gonadotropin. No suppression is documented, but endocrine effects of chronic exogenous administration in humans have not been studied.

Reproductive

No human data. Reproductive and developmental safety in humans is unknown and untested. Preclinical studies were in disease models, not reproductive-safety studies; use in pregnancy or when trying to conceive is not supported by any human safety evidence.

Neuropsychiatric

No human data. No neuropsychiatric adverse effects have been reported or systematically evaluated in humans.

Renal

No human data. Renal effects of administered MOTS-c are uncharacterized in humans. As a peptide subject to renal handling, effects in renal impairment are unknown.

Hematologic

No human data. Hematologic effects have not been evaluated in humans. Injectable non-sterile products carry a general (non-MOTS-c-specific) risk of bloodborne infection.

Dermatologic

No human data specific to the molecule. As with any subcutaneous injection of a non-pharmaceutical peptide, injection-site reactions (pain, redness, swelling), and infection/abscess from non-sterile product or technique are plausible practical hazards, though not formally studied for MOTS-c.

Recovery

HPTA suppression & recovery

Suppression: None documented / not applicable on current evidence

MOTS-c is a mitochondrial metabolic peptide, not an anabolic-androgenic steroid, SARM, or gonadotropin, and there is no evidence it suppresses the hypothalamic-pituitary-gonadal axis. However, HPTA effects of chronic exogenous administration have never been studied in humans, so absence of a documented signal is not proof of no effect. Any concern about hormonal or testicular-axis function should be evaluated and managed by an endocrinologist; recovery/HPTA management is out of scope for a compound with no human endocrine data, and dual-SERM protocols are not appropriate or discussed.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline comprehensive metabolic panel (glucose, renal and liver markers)Fasting glucose and HbA1c (AMPK/insulin-sensitizing mechanism could theoretically affect blood sugar, especially with diabetes medications)Fasting lipid panelCBCClinician-directed additional testing based on individual risk

Cadence: If used at all, obtain baseline labs before starting and repeat periodically (e.g., every 8-12 weeks) under a clinician's direction; there is no validated monitoring schedule because no human data exist.

Warning signs — seek care
  • Signs of hypoglycemia (shakiness, sweating, confusion, palpitations), particularly if also taking insulin or other glucose-lowering agents
  • Injection-site infection: spreading redness, warmth, swelling, pus, or fever — seek medical care
  • Any allergic/systemic reaction: rash, hives, swelling, difficulty breathing — seek emergency care
  • New unexplained or severe symptoms of any kind — stop and consult a clinician, since the adverse-effect profile in humans is unknown
Do not use if

Contraindications

  • No human safety data exist, so use cannot be considered safe in any population; this is an experimental, unapproved substance
  • Pregnancy, breastfeeding, or attempting to conceive — no human reproductive/developmental safety data
  • Known or suspected malignancy — growth/metabolic signaling effects of chronic administration in humans are unknown
  • Any use of non-sterile, unverified, or research-labeled injectable material (infection, contamination, unknown identity/purity)
  • Self-administration without medical supervision and baseline/follow-up bloodwork
  • Known hypersensitivity to the peptide or excipients/diluent
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Understand the core limitation: there is no human safety, toxicology, or dosing evidence for injected MOTS-c. Reported benefits come from mice, rats, and cell studies, which frequently fail to translate to humans.
  • This is an unapproved, unregulated substance. Products sold as MOTS-c have unverified identity, purity, dose accuracy, and sterility; contamination and mislabeling are real hazards independent of the peptide itself.
  • Do not use if pregnant, breastfeeding, trying to conceive, or if you have an active cancer — human safety in these situations is completely untested.
  • If you have diabetes or take glucose-lowering drugs, be aware of a theoretical hypoglycemia risk from AMPK/insulin-sensitizing mechanisms; do not adjust prescribed medication on your own and involve your clinician.
  • Get baseline bloodwork (metabolic panel, glucose/HbA1c, lipids, CBC) and periodic follow-up through a clinician; do not self-manage.
  • Stop immediately and seek medical care for signs of infection at an injection site, allergic reaction, hypoglycemia, or any severe/unexplained symptom.
  • Because the human adverse-effect profile is unknown, treat any new symptom as potentially related and discuss discontinuation with a physician.
  • Discuss with a qualified physician before use; the safest evidence-based route to MOTS-c's proposed metabolic benefits is exercise, which raises the body's own MOTS-c naturally.
Evidence

Citations (11)

Every clinical claim above is tied to a primary source. Overall evidence grade D — this compound lacks adequate human data; claims rest on preclinical or mechanistic evidence.

  1. 01

    MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame in the mitochondrial 12S rRNA region; it activates AMPK, inhibits the folate cycle/de novo purine biosynthesis, and improved insulin sensitivity and reduced diet-induced obesity/insulin resistance in mice.

    PreclinicalThe mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.PMID 25738459 ↗

  2. 02

    Under metabolic stress MOTS-c translocates to the nucleus and regulates nuclear gene expression via AMPK and antioxidant-response (NRF2/ARE) transcription factors.

    PreclinicalThe Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.PMID 29983246 ↗

  3. 03

    MOTS-c administration enhanced physical performance and healthspan in young, middle-aged, and old mice; in humans, exercise induces endogenous MOTS-c expression in skeletal muscle and circulation (no human administration).

    PreclinicalPMID 33473109 ↗

  4. 04

    In humans, circulating endogenous MOTS-c levels are reduced in type 2 diabetes and altered in obesity and correlate with lipid measures (total cholesterol, LDL) — observational data on the body's own peptide, not on administered MOTS-c.

    Meta-analysisPMID 39160573 ↗

  5. 05

    MOTS-c is a mitochondrial-derived peptide whose plasma level declines with age and which has been proposed for metabolic and aging-related conditions, but no effective clinical application has been developed (no human therapeutic data).

    ReviewMOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.PMID 36761202 ↗

  6. 06

    MOTS-c's relationships to diabetes and aging-related disease are based on mitochondrial-encoded-peptide biology and remain investigational, without established human treatment use.

    ReviewPMID 36824008 ↗

  7. 07

    MOTS-c improved insulin sensitivity/glucose tolerance and protected pancreatic beta-cells in a gestational-diabetes mouse model (preclinical).

    PreclinicalThe mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.PMID 34798268 ↗

  8. 08

    MOTS-c reduced fat accumulation and improved insulin resistance via AMPK in an ovariectomy mouse model of postmenopausal metabolic dysfunction (preclinical).

    PreclinicalPMID 30725119 ↗

  9. 09

    MOTS-c reduced ferroptosis and acute lung injury via PPARγ signaling in rats/cells; circulating endogenous MOTS-c was lower in post-CABG acute lung injury patients (interventional data preclinical; human data observational).

    PreclinicalPMID 37290680 ↗

  10. 10

    MOTS-c modulated systemic and cardiac NLRP3 inflammasome activity and lowered blood glucose/CRP in a diabetic rat model (preclinical).

    PreclinicalPMID 42321010 ↗

  11. 11

    MOTS-c is associated with exercise-related mitohormesis and enhances rodent metabolic adaptation and thermogenesis; human relevance is mechanistic/observational.

    ReviewPMID 35656563 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice